Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide
- PMID: 20172036
- DOI: 10.1016/j.vascn.2010.02.007
Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide
Abstract
Introduction: Pharmacological inhibition of cardiac potassium channels encoded by hERG (human ether-à-go-go-related gene) is associated with QT interval prolongation and torsades de pointes arrhythmia. Electrophysiological assays of hERG channel inhibition are integral to the safety testing of novel drug candidates. This study was conducted to compare, for the high affinity hERG inhibitors dofetilide and cisapride, hERG blockade between action potential (AP) and conventional (step and step-ramp) screening waveforms. Furthermore, it evaluated dynamic (pulse-by-pulse) protocol-dependence of hERG channel inhibition by these drugs.
Methods: Whole-cell patch-clamp recordings were made at 37 degrees C from hERG-expressing HEK 293 cells. Half-maximal inhibitory concentrations (IC(50) values) for I(hERG) blockade were obtained using conventional voltage clamp and action potential clamp, using previously digitised ventricular and Purkinje fibre (PF) AP waveforms.
Results: A more marked variation in IC(50) values with different command waveforms was observed for cisapride (ranging from 7 to 72 nM) than for dofetilide (ranging from 4 to 15 nM), with higher IC(50)s obtained with AP than step or step-ramp commands. The two drugs differed little from one another in effects on voltage-dependent activation; however, I(hERG) blockade by each drug was initially voltage-dependent, but at steady-state was only voltage-dependent for cisapride. There was comparatively little difference between the two drugs in effects on I(hERG) availability or time constants of development of inactivation. Features of time-dependence of blockade and the use of protocols employing varying rest periods in drug or commands of alternating duration highlighted a pronounced ability of cisapride, but not dofetilide, to dissociate and reassociate from hERG on a pulse-by-pulse basis.
Discussion: Protocols described here that demonstrated dynamic variation (drug dissociation/reassociation) in hERG channel current blockade at 37 degrees C for cisapride may have future value for investigating drug interactions with the hERG channel. Downloadable digitised ventricular and PF AP waveforms that can be used in AP clamp experiments also accompany this article.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.J Cardiovasc Electrophysiol. 2004 Nov;15(11):1302-9. doi: 10.1046/j.1540-8167.2004.04099.x. J Cardiovasc Electrophysiol. 2004. PMID: 15574182
-
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.FEBS Lett. 1997 Nov 3;417(1):28-32. doi: 10.1016/s0014-5793(97)01249-0. FEBS Lett. 1997. PMID: 9395068
-
Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.J Cardiovasc Electrophysiol. 2011 Oct;22(10):1163-70. doi: 10.1111/j.1540-8167.2011.02060.x. Epub 2011 Apr 13. J Cardiovasc Electrophysiol. 2011. PMID: 21489024
-
Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.J Appl Toxicol. 2009 Apr;29(3):183-206. doi: 10.1002/jat.1395. J Appl Toxicol. 2009. PMID: 18988205 Review.
-
Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.Curr Top Med Chem. 2016;16(16):1792-818. doi: 10.2174/1568026616666160315142156. Curr Top Med Chem. 2016. PMID: 26975508 Review.
Cited by
-
Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.Pharmaceuticals (Basel). 2023 Aug 24;16(9):1204. doi: 10.3390/ph16091204. Pharmaceuticals (Basel). 2023. PMID: 37765012 Free PMC article.
-
Predicting hERG repolarization power at 37°C from recordings at room temperature.Clin Transl Med. 2023 May;13(5):e1266. doi: 10.1002/ctm2.1266. Clin Transl Med. 2023. PMID: 37199999 Free PMC article. No abstract available.
-
Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment.Front Pharmacol. 2023 Mar 20;14:1110555. doi: 10.3389/fphar.2023.1110555. eCollection 2023. Front Pharmacol. 2023. PMID: 37021055 Free PMC article.
-
Safety pharmacology in 2022: Taking one small step for cardiovascular safety assay development but one giant leap for regulatory drug safety assessment.J Pharmacol Toxicol Methods. 2022 Sep-Oct;117:107206. doi: 10.1016/j.vascn.2022.107206. Epub 2022 Aug 1. J Pharmacol Toxicol Methods. 2022. PMID: 35926772 Free PMC article.
-
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.Front Cardiovasc Med. 2021 May 4;8:645172. doi: 10.3389/fcvm.2021.645172. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34017865 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
